---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-029492"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2022-10-25T23:59:59+00:00"
generated_at: "2026-06-23T01:15:09.315676+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics CEO letter details $5.1M financing, plans for 30-patient NB1 trial in Australia by 2023

## Summary
- Raised $5.1M gross in underwritten public offering of common stock and warrants for clinical trials and working capital.
- Modified license agreement with UCLA TDG in May 2022 to defer diligence fees until first product sale.
- Engaged MTF Biologics for DBM supply and a CDMO for recombinant protein manufacturing for NB1.
- Expects to commence 30-patient pilot study in Australia in 2023 evaluating NB1 in lumbar interbody fusion.
- NB1 addresses $3B global market for bone graft substitutes in spine fusion.

## SEC filing metadata
- accession: 0001493152-22-029492
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2022-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315222029492/0001493152-22-029492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315222029492/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-029492
- JSON: https://secwatch.observer/filing/0001493152-22-029492.json
- Plain text: https://secwatch.observer/filing/0001493152-22-029492.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.